拉米夫定序贯/联合阿德福韦酯治疗慢性乙型肝炎79例疗效分析
[摘要]目的 探讨拉米夫定序贯/联合阿德福韦酯治疗慢性乙型肝炎的临床疗效。 方法 选取我院2011年1月～2013年1月收治的慢性乙型肝炎患者79例，随机分为序贯组（40例）和联合组（39例），两组均常规予以保肝治疗，序贯组予以拉米夫定序贯阿德福韦酯进行治疗，联合组予以拉米夫定联合阿德福韦酯进行治疗，比较分析两组的临床疗效。 结果 联合组用药12个月和24个月时的肝功能指标改善程度显著优于序贯组（P<0.05）；两组HBeAg、HBV DNA转阴率无明显差异（P>0.05），HBV DNA定量显著低于序贯组（P<0.05）；联合组用药12个月、24个月的拉米夫定耐药突变率分别为10.3%、2.6%，显著低于序贯组的35.0%、20.0%（P<0.05）；两组阿德福韦酯的耐药突变率无明显差异（P>0.05）。 结论 拉米夫定联合阿德福韦酯片治疗慢性乙型肝炎具有显著疗效，耐药率低，值得进一步研究应用。
[关键词]拉米夫定；性慢性乙型肝炎；治疗效果
[中图分类号] R512.62 [文献标识码] B [文章编号] 2095-0616（2014）13-61-04
[Abstract]Objective To investigate the clinical efficacy of lamivudine and adefovir sequential or combined in treatment of chronic hepatitis B. Methods 79 patients with chronic hepatitis B in our hospital between January 2011 and January 2013 were randomly divided into sequential group （40 cases） and the combination group （39 cases）， both groups were received routine liver treatment.the sequential group received lamivudine adefovir sequential treatment， the combination group received lamivudine combined adefovir treatment. The clinical efficacy of the two groups was comparative analysised. Results The degree of improvement in liver function in combination group for 12 months and 24 months were significantly better than the sequential group （P<0.05）； HBeAg abd HBV DNA negative rate in two groups was no significant difference （P>0.05）， HBV DNA quantification was significantly lower than the sequential group （P<0.05）； combined group treatment for 12 months， the rate of...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
